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SARS- CoV- 2 infection has emerged as not only a pulmonary but also potentially multi- 
organ disease, which may cause long- term structural damage of different organ sys-
tems including the lung, heart, vasculature, brain, liver, kidney, or intestine. As a result, 
the current SARS- CoV- 2/COVID- 19 pandemic will eventually yield substantially in-
creased numbers of chronically diseased patients worldwide, particularly suffering from 
pulmonary fibrosis, post- myocarditis, chronic heart failure, or chronic kidney disease. 
Exercise recommendations for rehabilitation are complex in these patients and should 
follow current guidelines including standards for pre- exercise medical examinations and 
individually tailored exercise prescription. It is of utmost importance to start exercise 
training at an early stage after COVID- 19 infection, but at the same time paying atten-
tion to the physical barriers to ensure safe return to exercise. For exercise recommenda-
tions beyond rehabilitation programs particularly for leisure time and elite athletes, more 
precise advice is required including assessment of sports eligibility and specific return- 
to- sports exercise programs. Because of the current uncertainty of long- term course of 
SARS- CoV- 2 infection or COVID disease, long- term follow- up seems to be necessary.
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in any 
medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
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1 |  COVID- 19:  A SYSTEMIC 
DISEASE
The view of SARS- CoV- 2 as a primary respiratory patho-
gen has been challenged when increasing reports on multi- 
organ manifestation involving lung, heart, kidney, intestine, 
and brain had been reported.1,2 This multi- organ manifesta-
tion of coronavirus disease- 19 (COVID- 19) can be explained 
by the different pathomechanisms that all contribute to the 
deleterious systemic effects of SARS- CoV- 2 infection3- 8 :(a) 
Entry of SARS- CoV- 2 into cells via binding to the ACE- 2 re-
ceptor, a ubiquitously present membrane receptor, (b) Down- 
regulation of ACE- 2 inducing a decrease in anti- fibrotic 
Ang1- 7 and an increase in pro- fibrotic angiotensin, (c) Over- 
activation of the innate immune system leading to a cytokine 
release syndrome (CRS), (d) Induction of a ubiquitously ob-
served endothelialitis, accompanied by (e) Procoagulatory 
effects and induction of microthrombi. Overall, COVID- 19 
disease, particularly in case of a severe course with long- 
term bed rest, mechanical ventilation, and multi- organ in-
volvement will lead to significant physical and functional 
deconditioning affecting the whole organism (Figure  1). 
Moreover, organ tissue damage and degree of morphological 
as well as functional recovery after the acute phase of the 
lungs, myocardium, neurological system, kidneys, and pe-
ripheral musculature will result in reduced exercise capacity 
at short and long term. Exercise training has been shown to 
improve exercise capacity as well as quality of life during re-
habilitation of patients with various chronic diseases,9 and we 
hypothesize that also COVID- 19 patients will benefit from 
it, especially when organ- specific exercise prescription is ap-
plied. Exercise tolerance is impaired in COVID- 19 patients 
particularly in case of pulmonary involvement, but involve-
ment of other organs will have additional deleterious effects 
(Figure 1). Development of pulmonary fibrosis may reduce 
CO diffusing capacity. Moreover, pulmonary artery hyper-
tension caused by distortion and destruction of the pulmo-
nary vascular bed,3 hypoxia- induced vasoconstriction, and 
pulmonary artery thromboembolism will have a substantial 
impact on exercise tolerance. Furthermore, this can be poten-
tiated by reduced ejection fraction when the heart is involved 
as in COVID- 19 myocarditis.10 These cardio- pulmonary 
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impairments may be accompanied by thromboembolic com-
plications of COVID- 19 presenting as ischemic and (less 
frequently) hemorrhagic stroke.11,12 Like other infections, 
COVID- 19 may also induce encephalopathy12 or peripheral 
neuropathy11 including inflammation of peripheral myelin 
sheaths leading to Guillain- Barre syndrome or even central 
variants like the Miller- Fisher syndrome.13,14 Whether these 
acute alterations persist in COVID- 19 patients after clinical 
recovery is rather likely, but remains to be seen.
2 |  RATIONALE FOR EXERCISE- 
BASED REHABILITATION AFTER 
COVID- 19
Immobility particularly during severe courses of COVID- 19 
with intensive care treatment and mechanical ventilation pos-
sibly for weeks will significantly lead to a substantial decline 
in physical functioning (Figure 1). Even milder forms of dis-
ease will have systemic symptoms such as fever and myalgia, 
which will also reduce physical activity for some time during 
the acute phase and reduce exercise capacity as well. The full 
clinical picture becomes even more complicated in patients 
with multi- organ involvement (Figure 1).
As exercise training has shown to have substantial ben-
eficial effects and is recommended as standard therapy in 
pulmonary disease, for example, fibrosis or pulmonary hy-
pertension,15- 17 heart failure,18 kidney disease19,20 as well 
sarcopenia,21 exercise programs for post- COVID- 19 patients 
are absolutely mandatory.22,23 These patients have to be inte-
grated into general rehabilitation programs, which also con-
sider COVID- 19- specific comorbidities. Exercise training 
should be supervised during the early phase of rehabilitation, 
for example, during in- hospital or in group exercises and can 
be added and later confined to non- supervised training in a 
home- based setting or in a fitness gym. Support by telemed-
icine should be considered as an additional tool to increase 
long- term adherence to rehabilitation programs.24,25
Beyond general COVID- 19 rehabilitation, young and 
previously physically active individuals or even athletes in-
volved in competitive sports will have a special interest to 
return- to- sports and exercise on a leisure time or competition 
level. For them, specific recommendations for pre- exercise 
examinations as well as exercise training are necessary26 
(Figure 2). Currently, it is unclear whether mild courses of 
SARS- CoV- 2 infection have the potential to induce pro-
longed organ impairment, for example, subclinical reduction 
in lung diffusion capacity after pneumonia that may limit 
maximal exercise capacity. Therefore, a clinical examination 
has to be performed in all individuals after COVID- 19 before 
starting a rehabilitation program or an individualized training 
program in athletes (Figure 2).
F I G U R E  2  Algorithm for decision- making on exercise recommendations in patients and athletes after SARS- CoV- 2 infection and COVID- 19. 
*Recommendations for follow- up intervals are based on authors’ consensus, due to the paucity of scientific evidence on long- term impact of 
SARS- CoV- 2 infection on cardio- pulmonary function. **Recommendations are based on current guidelines28
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As pneumonia and myocarditis pose the potential for 
cardio- pulmonary limitations, increased risk and reduced 
maximal exercise performance, symptoms as well as clinical 
examination, will have to focus on these entities (Figure 2). In 
leisure time and elite athletes, recommendations for return- 
to- sport and eligibility for competitive sports depend on clin-
ical and functional recovery, the kind of organ involvement 
and the type of sport, for example, skill, power, mixed, or 
endurance.27,28
From our perspective, in elite and recreational athletes, 
basic routine medical re- evaluation including a resting ECG 
and blood analysis should be performed after 3- 6 months in 
order to assess currently unknown long- term effects of SARS- 
CoV- 2 infection. However, many especially young athletes 
have no or very few symptoms initially, so that in these cases 
individualized guidance based on initial symptoms may be 
more meaningful. Whether additional examinations are nec-
essary beyond this period has to be decided on an individual 
basis. In case of pulmonary or myocardial disease, regular 
in- depth cardiological examination including exercise test-
ing with arterial blood gases and optimally spiroergometry 
are recommended in addition to ECG and echocardiography 
on an annual basis at least for the first two years (Figure 2). 
Leisure time and elite athletes will be followed on a routine 
basis at least in yearly intervals.
3 |  DIAGNOSTICS BEFORE 
STARTING EXERCISE IN COVID- 19 
PATIENTS
As SARS- CoV- 2 may affect multiple organ systems, ex-
ercise recommendations can only be applied after a sound 
clinical examination (Figure 2). These diagnostic measures 
should follow an algorithm that takes into consideration the 
severity of the disease course, age, as well as post- disease 
exercise performance.29 Besides detailed history taking 
and physical examination, a blood analysis should assess 
parameters of inflammation, blood cell count, kidney func-
tion, and cardiac biomarkers in case of previous myocar-
ditis or pneumonia. Special focus should be laid on testing 
lung and myocardial function, which may be supplemental 
diagnostics, for example, neurological tests. Diagnostics 
are particularly not easy in case of suspected myocarditis, 
as this very much depends on the timing of initial evalu-
ation from first signs/symptoms of infection as well as a 
combination of symptoms, cardiac markers, ECG changes, 
and structural changes examined by echocardiography and/
or cardiac MR scan.
Moreover, as data for COVID- 19 and long- term prognosis 
have not yet been established, recommendations are extrapo-
lated from current understandings of other virus- induced pa-
thologies, but may change when more data become available. 
Because of the unknown long- term prognosis of SARS- 
CoV- 2 infection, we recommend follow- up examinations in 
shorter intervals (Figure 2).
3.1 | Pulmonary diagnostics
It is known from previous SARS epidemics that patients pre-
senting during a 2- year follow- up revealed impaired diffu-
sion capacity with overall decreased exercise performance 
capacity,30 a finding that is also observed for COVID- 19.31 
Therefore, standard workup for athletes should include static 
and dynamic lung function testing for assessment of vital ca-
pacity and forced expiratory volumes. Because of the fibrotic 
features of COVID- 19, measurements of residual volume 
and total lung capacity by body plethysmography are recom-
mended in those with priory proven pulmonary involvement 
or symptomatic athletes/patients with signs of persistent 
respiratory limitations like dyspnea or persistent bronchial 
hyperreactivity. In these patients, exercise testing including 
either oxygen saturation measurements during exercise or 
blood gas analysis before and after maximal exercise is advis-
able, as it will unmask impairment of diffusion capacity. The 
fall of oxygen saturation during exercise (<94%) is indicative 
of significant lung diffusion impairment, while mild forms 
of impairment may only be detected by measurements of ar-
terial blood gases during cardiopulmonary exercise testing 
(CPET).29,32 During CPET, special focus should additionally 
be laid on parameters of respiratory efficiency (ventilatory 
equivalents). Moreover, increased values for dead space at 
rest may resemble bronchial hyperreactivity and air trapping, 
a known finding after viral pneumonia.33 In case of persistent 
dyspnoea or otherwise unexplained limitation of exercise ca-
pacity, measurement of inspiratory muscle strength capacity 
may also be included into the clinical workup.34
3.2 | Cardiovascular diagnostics
Since cardiovascular involvement including inflammation 
of the coronary endothelium and myocardium has been re-
ported in COVID- 19, cardiovascular screening in recovered 
COVID- 19 patients is mandatory before starting exercise 
training (Figure 2). Therefore, a resting ECG is required in 
every person (even if asymptomatic) prior to return- to- sports, 
exercise, or physical activity (Figure 2). Even in patients with 
previous or ongoing mild symptoms, for example, palpita-
tions or dyspnea on exertion or an abnormal resting ECG, 
echocardiography should be added. In those with myocardial 
involvement during the acute phase, echocardiography is 
obligatory. Particularly myocardial involvement in SARS- 
CoV- 2- infection, even in those with only mild symptoms, 
may be detected by specific speckle tracking deformation 
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abnormalities.35 Therefore, this sensitive echocardiographic 
procedure should optimally be included in those with incon-
clusive myocardial findings or clinical evidence for myo-
carditis even in the presence of normal systolic function. If 
clinical examination, ECG or echocardiography, is sugges-
tive of myocarditis, which seems to be present in only about 
1% of young student and professional athletes suffering from 
COVID- 19,36,37 a cardiac MRI (CMR) has to be performed 
using all modern modalities (eg, late gadolinium enhance-
ment, T2 imaging, T1 mapping) to assess possible myocar-
dial involvement (Figure 2).
3.3 | Cardio- pulmonary exercise diagnostics
Before return- to- sport, the cardio- pulmonary system has to 
be evaluated during maximal exercise (Figure 2). Therefore, 
even in patients with COVID- 19 and only light symptoms, 
an exercise ECG including measurement of O2- saturation is 
advisable in order to detect subclinical impairment, for exam-
ple, arrhythmias or premature dyspnoea as in impaired lung 
diffusion capacity. Patients with more severe symptoms and/
or post- pneumonia or myocarditis should undergo spiroer-
gometry with blood gas analysis.29,32 Then, exercise- related 
parameters relevant for respiratory efficacy like the breathing 
equivalents and the O2- pulse as global measures of dysfunc-
tion of the cardio- pulmonary system are of particular inter-
est. In case results from previous pre- participation screenings 
exist, results should be compared and preferably, identical 
protocols should be applied for comparison.
Most importantly exercise prescription should be individ-
ually tailored, and precise advices concerning exercise du-
ration and exercise intensity should be given. Therefore, a 
maximal CPET or exercise protocol including lactate testing 
should be performed.38 These data will help guide training 
intensities particularly during early phases of return- to- play 
concepts. Increases of exercise intensity and volume should 
be introduced with caution and might take weeks to months 
until the pre- infection status— if ever— is reached.30
3.4 | Muscular and neurological testing
Due to the high likelihood of neurological involvement even 
in mild forms of COVID- 19, every patient should undergo 
a clinical neurological exam before returning to exercise. 
Emphasis should be given to motor, sensory, and coordi-
nation testing, but cranial and peripheral nerves should be 
carefully evaluated as well. Olfactory and gustatory dysfunc-
tions should be assessed,39 but are per se no contraindication 
to prescribe moderate- intensity exercise. Vertigo, however, 
needs to be evaluated carefully by examining the vestibulo- 
ocular system, because its persistence will impair exercise 
performance and may also affect safety during sports and 
exercise. Continuation of vertiginous symptoms will prompt 
further testing. Particularly a history of thromboembolic 
complications in the context of neurological symptoms will 
make an MRI of the brain inevitable to screen for cerebral 
embolisms and to assess the cerebral vasculature that may 
be affected by COVID- 19.39 Patients with a history of nerve 
entrapment may benefit from nerve conduction studies and 
electromyography and if dysexecutive syndromes are pre-
sent, cognitive screening or possibly a formal neuropsycho-
logical exam might be helpful.
4 |  EXERCISE TRAINING AFTER 
COVID- 19
Despite the multi- organ involvement (Figure  1), exercise 
training should be encouraged in all patients after discharge 
from hospital or after overall recovery from acute infection. 
In addition to the clinical severity and time course, perfor-
mance will be lost due to the illness per se, but also due to 
bed rest and long periods of deconditioning. As different and 
unpredictable as the characteristics of the clinical symptoms 
can vary between individuals with COVID- 19, recommenda-
tions regarding “return- to- sport” have to be made based on 
analogies from similar viral infections and organ involve-
ment, as controlled studies are currently lacking. However, 
it is unequivocal that exercise training has to be individually 
tailored in order to optimize the balance between strain and 
adaptation processes on the basis of disease state and exercise 
performance. With this in mind, the German Sports Medicine 
Association and American College of Cardiology's Sports & 
Exercise Cardiology Council have recently published expert 
consensus statements on this matter for post- COVID- 19 pa-
tients and athletes.29,40 If full eligibility is determined by the 
recommended diagnostics and no structural damage remains, 
athletes can gradually return to their specific training and to 
competitive activities (Figure 2). However, when myocardi-
tis or pneumonia have been present, more detailed medical 
analyses have to be performed including spiroergometry, 
echocardiography, and preferably CMR.41 In case of myocar-
ditis, depending on clinical and diagnostic findings, exercise 
may earliest be resumed after 3 months, but in most cases not 
before after 6 months or longer.27
In clinical practice, 2- 3 days of graded return should be 
considered for each training day lost due to the illness. This 
seemingly long duration is based on the fact that, regard-
less of the direct, for example, virus- induced inflammation 
or indirect effects (eg, mechanical ventilation), recovery of 
pulmonary tissue and vasculature is prolonged even when 
virus load has resolved. With regard to training structure, 
first frequency, then duration, and finally intensity should 
be increased. Monitoring of oxygen saturation and heart rate 
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during exercise is a viable and practical tool for guiding exer-
cise training during recovery periods.
In the following chapter, exercise recommendations will 
be given based on organ involvement due to COVID- 19 
based on current knowledge of rehabilitation concepts 
for primarily sedentary subjects, recreational as well as 
elite athletes competing at national or international level 
(Figure 2).
4.1 | Exercise after COVID- 19: Lung 
fibrosis, pulmonary hypertension, and 
bronchial hyperreactivity
The length of recovery from pneumonia varies depending 
on the clinical severity during acute COVID- 19 infection. 
Therefore, a decisive clinical pulmonary workup has to be 
performed before resuming exercise and sports (Figure  2). 
However, it is undisputable that exercise is a hallmark dur-
ing recovery periods from pulmonary disease, as there is clear 
evidence of significant clinical improvement in lung function 
by targeted respiratory rehabilitation (daily exercise program 
for at least 6 weeks, ≥10 min/d).5 This should initially include 
training of the in- and expiratory muscles using specific respir-
atory muscle training equipment to avoid pulmonary overload, 
the former including diaphragmatic breathing. Sustained maxi-
mal inspiration training will also lead to an even distribution 
of ventilation and thus to a reduction in atelectases. Expiratory 
muscle training will promote clearance of secretion.
Endurance exercise and pulmonary function training are 
added by resistance and flexibility training to improve pe-
ripheral adaptations. Interval training seems to be superior to 
moderate continuous training regarding adherence.17 Strength 
training should initially focus on a dynamic character, for 
example, 1- 3 sets of 15- 20 repetitions at moderate intensity 
(Borg CR10 scale: 4- 6).16 Even in pulmonary artery hyperten-
sion, exercise training has been shown to be safe and feasible 
without negative sequelae of right ventricular overload.17,42
In recreational or competitive athletes, impairment of pul-
monary function is a key limiting factor in endurance sports, 
but may be of less significance in skill or power sports. If 
pulmonary impairment persists, athletes may never achieve 
pre- COVID performance values. Nonetheless, a complex 
exercise training aiming at improvement in oxidative capac-
ity of the peripheral musculature with steady increment will 
compensate for cardio- pulmonary limitations and increase 
overall exercise performance.
4.2 | Exercise after COVID- 19: Myocarditis
Exercise training after acute myocarditis should be resumed 
in a setting of supervised rehabilitation including a structured 
exercise program (Figure  2). As myocarditis ranges from 
those with complete recovery to those with persistent myo-
cardial injury (positive LGE in CMR), training has to be in-
dividually adapted and eligibility for competitive sports has 
to be made on an individual basis.
Patients with an uncomplicated course of acute myocar-
ditis and complete recovery, including normal LV function 
without late gadolinium enhancement in CMR, have a very 
good prognosis.43,44 In these patients, exercise training of 
moderate intensity can be introduced 1 month after the acute 
phase, even if other limitations, for example, impaired lung 
function testing or gas exchange are lead findings, but should 
not be increased before three months27,41 (Figure 2). In case 
of pericarditis without myocarditis, exercise may be resumed 
mostly after 6 weeks of acute phase recovery.41
Patients and particularly athletes with recovered myocar-
dial function after initially impaired ejection fraction should 
be advised to refrain from structured high- intensity training 
or competitive sports for at least 3 but mostly 6 months.27,41 
Although the current course of myocardial disease in 
COVID- 19 is unclear, it is likely from previous experience 
with other SARS infections that viral load and chronic in-
flammation may persist even when clinical symptoms have 
subsided. A complete cardiac investigation (Figure  2) in-
cluding CPET will have to be performed for assessment of 
pathologies, but also for exercise intensity prescription.28,41 
First endurance exercise should start at moderate intensity 
(50%- 70% VO2max) for 4- 6  weeks before higher intensity 
exercise is resumed. Thereafter, full eligibility for competi-
tive sports can be approved in most cases (Figure 2). Patients 
and athletes who present with impaired myocardial func-
tion or myocardial fibrosis even after 6 months can resume 
moderate- intensity exercise.18 However, attesting eligibility 
for competitive sports in unresolved disease can likely not be 
attested particularly in endurance and mixed sports because 
of increased mortality rates44 amplified by exercise.
4.3 | Exercise after COVID- 19: 
Heart failure
Recently published recommendations authored by the 
Secondary Prevention and Rehabilitation Section of the 
European Association of Preventive Cardiology confirm the 
highest level of evidence for the effects of exercise- based car-
diac rehabilitation in all patients with heart failure, regardless of 
their left ventricular ejection fraction.9 Enrollment should occur 
right after hospital discharge and long- term aims should focus 
on a lifelong, heart healthy, and thus physically active lifestyle. 
Indeed, cardiac rehabilitation is well established in heart failure 
without COVID- 199 and there is no reason to believe that it 
was not effective in patients who recovered from COVID- 19. 
A recent systematic literature search summarized findings by 
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stating that COVID- 19 patients should be granted access to 
early cardiac rehabilitation and that if face- to- face contact is 
not an option, then tele- rehabilitation should be considered.24
Since medical therapy is part of secondary prevention, it 
is noteworthy that treatment with ACE inhibitors and ARBs 
has been found not to elicit excess mortality in heart failure 
patients and standard heart failure medication should not be 
altered in fear of untoward effects caused by SARS- CoV- 2.45
In addition, exercise training has to be individually tai-
lored, ideally during programs of cardiac rehabilitation 
where all types of endurance and resistance training may 
be considered, and individual choices can be made accord-
ing to disease stage, comorbidities, and current physical fit-
ness. No differentiation shall be made between HFpEF and 
HFrEF.18 As in heart failure patients without COVID- 19, 
in case of NYHA III, exercise intensity should initially be 
<40% of VO2peak during the first few weeks and can then be 
cautiously up- titrated to 50- 70% VO2peak for 30- 60 min/d.
9 
Higher intensities up to 85% VO2peak even as high- intensity 
interval training have been shown effective and can be chosen 
according to patients’ progress during exercise training and 
individual preference.46 Resistance exercise training supple-
ments aerobic exercise training and avoids or reverts loss of 
skeletal muscle and thus deconditioning. Weights should be 
chosen so that 2- 3 sets of 10- 15 repetitions can be performed. 
Respiratory training (15- 30  minutes, 30%- 60% of maximal 
inspiratory pressure) should be part of the training regime 
as in pulmonary disease to improve VO2peak, dyspnoea, and 
respiratory muscle competence.
4.4 | Exercise after COVID- 19: Chronic 
kidney disease
The prevalence of chronic kidney disease (CKD) and long- 
term hemodialysis will certainly increase with the SARS- 
CoV- 2 pandemic, as the infection has shown to affect the 
kidneys inducing dysfunction or even kidney failure par-
ticularly in patients with multiple organ involvement.1,47 
Evidence from current statistics reveals that 75% of CKD 
patients are frail and spend a sedentary lifestyle, exercis-
ing less than once a week, which is directly correlated with 
adverse health outcomes.48 Therefore, exercise training 
should be prescribed as early as possible, even during the 
acute phase, in order to maintain exercise capacity. Exercise 
should also be introduced in patients requiring hemodialysis. 
Then exercise can either be performed during hemodialysis 
(intradialytic exercise, eg, bed ergometry) or between dialy-
sis sessions (interdialytic exercise), the former with supe-
rior adherence and preferred option to improve efficacy of 
hemodialysis, physical fitness, cardiovascular risk factors, 
quality of life, and other health- related benefits.49 There is 
only limited experience regarding the definition of optimal 
intensity or duration of exercise, which is currently investi-
gated in large randomized trials (NCT03885102). In general, 
a low- to moderate- intensity endurance exercise training on a 
bed ergometer is recommended in combination of resistance 
and coordination training at least twice or thrice a week.49 
Because of a high prevalence of polyneuropathy and sarco-
penia, walking with the risk of falling is not recommended. 
To improve the latter, daily exercises for coordination should 
be included into daily life, optimally twice a day, combined 
with strength exercises. Intensity of exercise is mostly low, 
and adherence to the training protocol is the main target. If 
these regimens are followed, long- term adherence even over 
five years is good.50
If COVID- 19 leads to kidney function impairment or even 
kidney failure, kidney transplantation may become necessary. 
Full eligibility for non- contact sports is usually attested in 
clinically stable athletes after transplantation.
4.5 | Exercise after COVID- 19: 
Neurological disease
Similar to other organ manifestations of COVID- 19, no data 
on long- term outcome or complications of neurological pa-
thologies or effects of exercise on these are available so far. 
However, it can be expected that exercise will have positive 
effects on resaturation and plasticity of the nervous system 
like in other neurological disorders. Therefore, resuming or 
starting exercise is also highly desired from a neurological 
standpoint and should be encouraged in all patients. Patients 
with motor deficits, for example, COVID- 19- associated 
strokes or remaining vertigo need to be assessed according 
to their functional state and most likely benefit from exercise 
and physical therapy under professional supervision.
If athletes are affected by neurological complications of 
COVID- 19, exercise should be adapted to neurological re-
covery. Competitive sports are not restricted by neurological 
diseases per se, but athletes may be limited due to neurolog-
ical constraints.
5 |  PERSPECTIVE
In view of the systemic nature of COVID- 19, individualized 
training concepts for COVID- 19 patients in rehabilitation 
settings during the acute phase, early recovery phase, and 
beyond are mandatory. Patients intending to perform leisure 
time exercise training or even return to competitive sports 
will have to be specially guided. These recommendations 
should be differentiated in relation to level of exercise from 
ensuring independence in the fragile old patient to leisure 
time or elite athletes, pushing themselves to the limit in rela-
tion to exercise intensity and duration. For them a network of 
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physicians specialized in sports medicine, sports cardiology, 
pulmonology as well as sports and exercise physiologists 
will have to be established to guarantee safety and efficacy of 
training at the same time.
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